<p>Multiple myeloma (MM) frequently presents with gain or amplification of chr1q (1q+), which is associated with inferior response to treatment and poor outcomes. To develop targeted therapy for MM with 1q+, we leveraged external and in-house dependency screens and drug screens, along with single-cell sequencing of patient tumors with subclonal 1q+. We demonstrated that MM with 1q+ exhibits higher sensitivity to <a href="https://www.ncbi.nlm.nih.gov/gene/4170">MCL1</a> and PI3K inhibitors, which may be synergistic and act through established and novel mechanisms. Two human MM cell lines with 1q+, KMS12BM and KMS11, were profiled with either single-cell RNA-sequencing (scRNA-seq) alone (KMS12BM, KMS11) or both scRNA-seq and whole-genome sequencing (WGS; KMS12BM) to understand the factors that determine response to <a href="https://www.ncbi.nlm.nih.gov/gene/4170">MCL1</a> and PI3K inhibitors and how these inhibitors work.</p>

Developing Targeted Therapy for Patients with Multiple Myeloma and Gain    or Amplification of Chr1q (1q+)

Multiple Myeloma study with RNA-Seq, WGS data on dbGaP (7 participants)

Developing Targeted Therapy for Patients with Multiple Myeloma and Gain or Amplification of Chr1q (1q+)

Description

Applying For Access

Summary